Close

Goldman Sachs Positive on Incyte (INCY) Opzelura Launch Momentum Following NDR

November 24, 2021 8:10 AM EST Send to a Friend
Goldman Sachs analyst Salveen Richter reiterated a Buy rating and $136.00 price target on Incyte (NASDAQ: INCY) after hosting meetings ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login